The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
Official Title: SORINT - SORafenib for Treatment of Patients With INTermediate Stage Hepatocellular Carcinoma
Study ID: NCT01908322
Brief Summary: The study aims to investigate patient characteristics of intermediate stage hepatocellular carcinoma patients treated with Nexavar and their distribution to different treatment groups as well as determining efficacy and safety parameters.
Detailed Description:
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Many Locations, , Germany
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR